Healthcare / Medical Instruments & SuppliesTokyo
$670.00
+2.00 (+0.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $197.2M · quality 59.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.6B
P/E
14.1x
↓EV/EBITDA
7.9x
↓ROE
14.0%
↑Gross Margin
44.8%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+5.0%
FCF CAGR
+3.4%
FCF margin
10.9%
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.54B · net income $386.4M · FCF $386.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.54B | $3.54B | $3.19B | $3.12B | $3.06B |
| Net Income | $386.4M | $386.4M | $338.2M | $351.8M | $411.2M |
| EBITDA | $602.5M | $602.5M | $517.3M | $558.1M | $673.5M |
| EPS | 39.00 | 39.00 | 37.20 | 43.98 | — |
| Gross Margin | 44.8% | 44.8% | 44.8% | 45.6% | 47.9% |
| Operating Margin | 15.4% | 15.4% | 14.4% | 16.4% | 20.4% |
| Net Margin | 10.9% | 10.9% | 10.6% | 11.3% | 13.4% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 0.19 | 0.23 |
| Current Ratio | 6.99 | 6.99 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $386.4M | $386.4M | $172.2M | $197.2M | $349.5M |
| Returns | |||||
| ROE | 14.0% | 14.0% | 13.7% | 22.7% | 31.6% |
| Valuation | |||||
| P/E | 14.11 | 14.11 | 8.71 | — | — |
| EV/EBITDA | 7.86 | 7.86 | 2.35 | — | — |
| P/B | 2.40 | 2.40 | 1.19 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 11.1% | 11.1% | 2.4% | 1.7% | — |
| EPS Growth | 4.8% | 4.8% | -15.4% | — | — |
| Dividend Yield | 3.9% | 3.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.1%
EPS terminal req.
$59.45
Spread vs growth
-10.2%
5Y implied EPS CAGR
13.0%
EPS terminal req.
$71.94
Spread vs growth
-8.2%
10Y implied EPS CAGR
11.5%
EPS terminal req.
$115.85
Spread vs growth
-6.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+22.9%
Start / end P/E
15.1x → 17.2x
EPS bridge
37.20 → 39.00
Residual
+0.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.